Press Releases

Date Title and Summary
Toggle Summary Kezar Announces Closing of $56.8 Million Public Offering of Common Stock and Pre-Funded Warrants
SOUTH SAN FRANCISCO, Calif. , Feb. 04, 2020 (GLOBE NEWSWIRE) -- Kezar Life Sciences , Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing novel small molecule therapeutics to treat unmet needs in autoimmune disease and cancer, today announced the closing of an
Toggle Summary Kezar Announces Presentations During Upcoming Scientific Conferences
SOUTH SAN FRANCISCO, Calif. , May 20, 2020 (GLOBE NEWSWIRE) -- Kezar Life Sciences , Inc. (Nasdaq:  KZR ), a clinical-stage biotechnology company discovering and developing novel small molecule therapeutics to treat unmet needs in autoimmune disease and cancer, today announced presentations during
Toggle Summary Kezar Announces Pricing of $49.4 Million Public Offering of Common Stock and Pre-Funded Warrants
SOUTH SAN FRANCISCO, Calif. , Jan. 31, 2020 (GLOBE NEWSWIRE) -- Kezar Life Sciences , Inc. (Nasdaq:  KZR ), a clinical-stage biotechnology company discovering and developing novel small molecule therapeutics to treat unmet needs in autoimmune disease and cancer, today announced the pricing of an
Toggle Summary Kezar Announces Pricing of a Public Offering of $46.7 million of Common Stock and Pre-Funded Warrants
SOUTH SAN FRANCISCO, Calif. , June 08, 2020 (GLOBE NEWSWIRE) -- Kezar Life Sciences , Inc. (Nasdaq:  KZR ), a clinical-stage biotechnology company discovering and developing novel small molecule therapeutics to treat unmet needs in autoimmune disease and cancer, today announced the pricing of an
Toggle Summary Kezar Announces Promising New Data with KZR-616 at the American College of Rheumatology Annual Meeting
Step-up dose titration lowered GI side effects while maintaining clinical activity Majority of patients completing 13 weeks of treatment demonstrated significant improvement on at least 2 measures of disease activity Conference Call and Webcast today at 8:30am EST MISSION Phase 1b Study Design
Toggle Summary Kezar Announces Proposed Public Offering of Common Stock
SOUTH SAN FRANCISCO, Calif. , June 08, 2020 (GLOBE NEWSWIRE) -- Kezar Life Sciences , Inc. (Nasdaq:  KZR ), a clinical-stage biotechnology company discovering and developing novel small molecule therapeutics to treat unmet needs in autoimmune disease and cancer, today announced that it intends to
Toggle Summary Kezar Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
SOUTH SAN FRANCISCO, Calif. , Jan. 30, 2020 (GLOBE NEWSWIRE) -- Kezar Life Sciences , Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing novel small molecule therapeutics to treat unmet needs in autoimmune disease and cancer, today announced that it intends to
Toggle Summary Kezar Life Sciences Announces Acceptance of Abstract for Presentation of First in Patient Study with KZR-616 at EULAR 2019 Annual Meeting
Abstract highlights preliminary results from the first two cohorts of the Phase 1b portion of the MISSION Trial in patients with systemic lupus erythematosus (SLE) Detailed poster with additional results will be presented during EULAR 2019 in Madrid SOUTH SAN FRANCISCO, Calif.
Toggle Summary Kezar Life Sciences Announces Closing of Initial Public Offering and Exercise in Full of the Underwriters' Option to Purchase Additional Shares
SOUTH SAN FRANCISCO, Calif. , June 25, 2018 /PRNewswire/ --  Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing novel small molecule therapeutics to treat unmet needs in autoimmunity and cancer, announced today the closing of its initial
Toggle Summary Kezar Life Sciences Announces Initiation of Clinical Study to Test a New Drug Product Formulation of KZR-616
SOUTH SAN FRANCISCO, Calif. , March 06, 2019 (GLOBE NEWSWIRE) -- Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing novel small molecule therapeutics to treat unmet needs in autoimmunity and cancer, today announced the initiation of a Phase 1,